Full Year 2019 Product Revenues of $117.9 Million Increased 30% Over 2018 Record Quarterly Revenue and Profit in the Fourth Quarter Conference Call Today at.
Generated total full-year 2019 revenues of $31.8 million, driven primarily by Vericel license payment and development services to BARDA Initiated U.S. Phase 2 adaptive design.
CAMBRIDGE, Mass., Feb. 24, 2020 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that.
YAVNE, Israel, Feb. 18, 2020 -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn.
MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the expansion of its agree
MediWound Ltd. (MDWD) and its U.S. commercial partner Vericel Corporation (VCEL) today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) within the Assistant Secre
Statistically speaking, long term investing is a profitable endeavour. But unfortunately, some companies simply don't...
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE